{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T12:37:30Z","timestamp":1648816650053},"reference-count":32,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T00:00:00Z","timestamp":1330560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Medical Imaging and Radiation Sciences"],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1016\/j.jmir.2011.12.004","type":"journal-article","created":{"date-parts":[[2012,1,29]],"date-time":"2012-01-29T12:16:35Z","timestamp":1327839395000},"page":"43-51","source":"Crossref","is-referenced-by-count":2,"title":["Factors Influencing Non-cardiac Side Effects of Dipyridamole When Used for Myocardial Perfusion Stress Testing"],"prefix":"10.1016","volume":"43","author":[{"given":"Robert","family":"Miner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jmir.2011.12.004_bib1","unstructured":"Crawford E, Husain S. Nuclear cardiac imaging: terminology and technical aspects. Society of Nuclear Medicine Technologist section. Reston, VA: Society of Nuclear Medicine;\u00a02003."},{"key":"10.1016\/j.jmir.2011.12.004_bib2","series-title":"Basic pathology","author":"Kumar","year":"2003"},{"key":"10.1016\/j.jmir.2011.12.004_bib3","series-title":"Evidence-based imaging","first-page":"252","article-title":"Cardiac evaluation: the current status of outcomes-based imaging","author":"Bierhals","year":"2006"},{"key":"10.1016\/j.jmir.2011.12.004_bib4","doi-asserted-by":"crossref","first-page":"399","DOI":"10.2967\/jnumed.107.033530","article-title":"Nuclear cardiac stress testing in the era of molecular medicine","volume":"49","author":"Vesely","year":"2008","journal-title":"J Nucl Med Technol"},{"key":"10.1016\/j.jmir.2011.12.004_bib5","series-title":"A clinician\u2019s guide to nuclear medicine","author":"Taylor","year":"2006"},{"key":"10.1016\/j.jmir.2011.12.004_bib6","series-title":"Myocardial perfusion imaging. A technologist\u2019s guide","author":"EANM","year":"2004"},{"key":"10.1016\/j.jmir.2011.12.004_bib7","series-title":"Nuclear cardiology technical applications","author":"Heller","year":"2009"},{"key":"10.1016\/j.jmir.2011.12.004_bib8","doi-asserted-by":"crossref","first-page":"14","DOI":"10.2967\/jnmt.108.057802","article-title":"Current methods of pharmacological stress testing and the potential advantages of new agents","volume":"37","author":"Botvinick","year":"2009","journal-title":"J Nucl Med"},{"key":"10.1016\/j.jmir.2011.12.004_bib9","series-title":"Nuclear cardiology technical applications","author":"Heller","year":"2009"},{"key":"10.1016\/j.jmir.2011.12.004_bib10","series-title":"SNM procedure guideline for myocardial perfusion imaging (version 3)","author":"Strauss","year":"2002"},{"key":"10.1016\/j.jmir.2011.12.004_bib11","first-page":"2107","article-title":"Safety of dipyridamole-thallium imaging in high risk patients with known or suspected coronary artery disease","volume":"32","author":"Perper","year":"1991","journal-title":"J Nucl Med Technol"},{"key":"10.1016\/j.jmir.2011.12.004_bib12","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s12350-009-9062-4","article-title":"ASNC imaging guidelines for nuclear cardiology procedures","volume":"16","author":"Henzlova","year":"2009","journal-title":"Am Soc Nucl Cardiol"},{"key":"10.1016\/j.jmir.2011.12.004_bib13","unstructured":"Boehringer Ingelheim. Persantine (dipyridamole) product insert. Boehringer Ingelheim Ltd, Burlington, Ontario, Canada. 2005; document number 22C071\/CA\/3."},{"key":"10.1016\/j.jmir.2011.12.004_bib14","unstructured":"British Pain Society and British Geriatrics Society. Guidance on the assessment of pain in older people. Available at: http:\/\/www.bgs.org.uk\/Publications\/Publication%20Downloads\/Sep2007PainAssessment.pdf. Accessed May 7, 2010."},{"key":"10.1016\/j.jmir.2011.12.004_bib15","unstructured":"National institute of health. Pain intensity instruments, 2003. http:\/\/painconsortium.nih.gov\/pain_scales\/index.html. Accessed May 7,\u00a02010."},{"key":"10.1016\/j.jmir.2011.12.004_bib16","unstructured":"Motulsky H. Prism 5 statistics guide. GraphPad Software Inc., San\u00a0Diego CA. 2007;12\u201313;122\u2013124. Available at: http:\/\/helpdesk.graphpad.com\/faq\/images\/Prism5Stats.pdf."},{"key":"10.1016\/j.jmir.2011.12.004_bib17","series-title":"Introduction to research in the health sciences","author":"Polgar","year":"2008"},{"key":"10.1016\/j.jmir.2011.12.004_bib18","first-page":"78","article-title":"Sample size estimation using Krejcie and Morgan and Cohen statistical power analysis: a comparison","volume":"7","author":"Chuan","year":"2006","journal-title":"J Penyelidkan"},{"key":"10.1016\/j.jmir.2011.12.004_bib19","series-title":"SPSS for psychologists","author":"Brace","year":"2006"},{"key":"10.1016\/j.jmir.2011.12.004_bib20","first-page":"21","article-title":"Adverse reactions to dipyridamole in patients undergoing stress\/rest cardiac perfusion testing","volume":"30","author":"Meyers","year":"2002","journal-title":"J Nucl Med Technol"},{"key":"10.1016\/j.jmir.2011.12.004_bib21","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S1071-3581(99)90105-8","article-title":"Myocardial stress testing: understanding the options","volume":"6","author":"White","year":"1999","journal-title":"J Nucl Cardiol."},{"key":"10.1016\/j.jmir.2011.12.004_bib22","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1111\/j.1468-2982.2006.01137.x","article-title":"Dipyridamole may induce migraine in patients with migraine without aura","volume":"26","author":"Kruuse","year":"2006","journal-title":"Cephalalgia"},{"key":"10.1016\/j.jmir.2011.12.004_bib23","first-page":"577","article-title":"Comparison of adenosine triphosphate and dipyridamole by thallium-201 myocardial scintigraphy","volume":"38","author":"Watanabe","year":"1997","journal-title":"J Nucl Med"},{"key":"10.1016\/j.jmir.2011.12.004_bib24","first-page":"1205","article-title":"The safety of intravenous dipyridamole thallium myocardial perfusion imaging. Intravenous dipyridamole thallium imaging study group","volume":"81","author":"Ranhosky","year":"1990","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jmir.2011.12.004_bib25","first-page":"1245","article-title":"Thallium-201-dipyridamole imaging: comparison between a standard dose and a high dose of dipyridamole in the detection of coronary artery disease","volume":"35","author":"Lalonde","year":"1994","journal-title":"J Nucl Med"},{"key":"10.1016\/j.jmir.2011.12.004_bib26","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2967\/jnmt.109.072629","article-title":"The association of dipyridamole side effects with hemodynamic parameters, ECG findings, and scintigraphy outcomes","volume":"38","author":"Javadi","year":"2010","journal-title":"J Nucl Med Technol."},{"key":"10.1016\/j.jmir.2011.12.004_bib27","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1007\/s002590050453","article-title":"Practicability and safety of dipyridamole cardiac imaging in patients with severe chronic obstructive pulmonary disease","volume":"26","author":"Thurnheer","year":"1999","journal-title":"Eur J Nucl Med."},{"key":"10.1016\/j.jmir.2011.12.004_bib28","first-page":"730","article-title":"Effect of caffeine intake on myocardial hyperemic flow induced by adenosine triphosphate and dipyridamole","volume":"45","author":"Kubo","year":"2004","journal-title":"J Nucl Med"},{"key":"10.1016\/j.jmir.2011.12.004_bib29","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1053\/j.semnuclmed.2008.12.003","article-title":"Current advances in vasodilator pharmacological stress perfusion imaging","volume":"39","author":"Druz","year":"2009","journal-title":"Semin Nucl Med."},{"key":"10.1016\/j.jmir.2011.12.004_bib30","doi-asserted-by":"crossref","first-page":"163","DOI":"10.2967\/jnmt.109.065581","article-title":"Advances in pharmacological stress agents: focus on Regadenoson","volume":"38","author":"Johnson","year":"2010","journal-title":"J Nucl Med Technol"},{"key":"10.1016\/j.jmir.2011.12.004_bib31","first-page":"114","article-title":"Adenosine versus regadenoson comparative evaluation in myocardial perfusion imaging: results of the ADVANCE phase 3 multicenter international trial","volume":"6","author":"Iskandrian","year":"2007","journal-title":"Am Soc Nucl Cardiol."},{"key":"10.1016\/j.jmir.2011.12.004_bib32","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.jcmg.2008.02.003","article-title":"Effects of age, gender, obesity, and diabetes on the efficacy and safety of the selective A2A agonist Regadenoson versus adenosine in myocardial perfusion imaging: integrated ADVANCE-MPI Trial Results","volume":"1","author":"Cerqueira","year":"2008","journal-title":"J Am Coll Cardiol Imaging"}],"container-title":["Journal of Medical Imaging and Radiation Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1939865411001342?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1939865411001342?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,26]],"date-time":"2018-11-26T15:50:15Z","timestamp":1543247415000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1939865411001342"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["S1939865411001342"],"URL":"https:\/\/doi.org\/10.1016\/j.jmir.2011.12.004","relation":{},"ISSN":["1939-8654"],"issn-type":[{"value":"1939-8654","type":"print"}],"subject":[],"published":{"date-parts":[[2012,3]]}}}